
    
      In addition to evaluating efficacy and safety, PREMISE will include a description of patient
      demographics, etiology of mitral regurgitation, co-morbidities, medication use and functional
      class. It will also compare re-hospitalization for heart failure 12 months prior and 12
      months after the procedure.
    
  